A recent study showed that, following treatment with histone deacetylase inhibitors (HDACs), a promising class of drug in prostate cancer, decreased recruitment of E2F1 results in downregulation of a few key DNA repair genes, leading to reduced DNA repair capacity and enhanced sensitivity to genotoxic agents43. The gene discussed is E2F1; the disease is prostate cancer.